|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008.
|
|
2
|
Nadkar A, Pungaliya C, Drake K, Zajac E,
Singhal SS and Awasthi S: Therapeutic resistance in lung cancer.
Expert Opin Drug Metab Toxicol. 2:753–777. 2006.
|
|
3
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008.
|
|
4
|
Wang X, Long M, Dong K, Lin F, Weng Y,
Ouyang Y, Liu L, Wei J, Chen X, He T and Zhang HZ: Chemotherapy
agents-induced immunoresistance in lung cancer cells could be
reversed by trop-2 inhibition in vitro and in vivo by
interaction with MAPK signaling pathway. Cancer Biol Ther.
14:1123–1132. 2013.
|
|
5
|
Li HL, Xie SM, Zhang L, Cai CJ, Wang W,
Huang J, Wang DY, Wen DP, Deng QH, Zhong NS and He JX:
Establishment and characterization of a new drug surviving cell
line Am1010, derived directly from muscle metastases of a human
lung adenocarcinoma patient with multi-drug-resistance to
cisplatin, taxol, and gefitinib. Acta Pharmacol Sin. 31:601–608.
2010.
|
|
6
|
Prestwich RJ, Errington F, Hatfield P,
Merrick AE, Ilett EJ, Selby PJ and Melcher AA: The immune system -
is it relevant to cancer development, progression and treatment?
Clin Oncol (R Coll Radiol). 20:101–112. 2008.
|
|
7
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: a systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011.
|
|
8
|
Sharma P, Shen Y, Wen S, Yamada S,
Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and
Sato E: CD8 tumor-infiltrating lymphocytes are predictive of
survival in muscle-invasive urothelial carcinoma. Proc Natl Acad
Sci USA. 104:3967–3972. 2007.
|
|
9
|
Staibano S, Mascolo M, Tranfa F, Salvatore
G, Mignogna C, Bufo P, Nugnes L, Bonavolontà G and De Rosa G: Tumor
infiltrating lymphocytes in uveal melanoma: a link with clinical
behavior? Int J Immunopathol Pharmacol. 19:171–179. 2006.
|
|
10
|
Nakamura H, Saji H, Ogata A, Hosaka M,
Hagiwara M, Kawasaki N, Konaka C and Kato H: Immunologic parameters
as significant prognostic factors in lung cancer. Lung Cancer.
37:161–169. 2002.
|
|
11
|
Pelletier MP, Edwardes MD, Michel RP,
Halwani F and Morin JE: Prognostic markers in resectable non-small
cell lung cancer: a multivariate analysis. Can J Surg. 44:180–188.
2001.
|
|
12
|
Shultz LD, Schweitzer PA, Christianson SW,
Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV,
Greiner DL, et al: Multiple defects in innate and adaptive
immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191.
1995.
|
|
13
|
Smit JK, Faber H, Niemantsverdriet M,
Baanstra M, Bussink J, Hollema H, van Os RP, Plukker JT and Coppes
RP: Prediction of response to radiotherapy in the treatment of
esophageal cancer using stem cell markers. Radiother Oncol.
107:434–441. 2013.
|
|
14
|
Yamauchi Y, Izumi Y, Asakura K, Kawai K,
Wakui M, Ohmura M, Suematsu M and Nomori H: Lewis lung carcinoma
progression is facilitated by TIG-3 fibroblast cells. Anticancer
Res. 33:3791–3798. 2013.
|
|
15
|
van der Loo JC, Hanenberg H, Cooper RJ,
Luo FY, Lazaridis EN and Williams DA: Nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mouse as a model system to
study the engraftment and mobilization of human peripheral blood
stem cells. Blood. 92:2556–2570. 1998.
|
|
16
|
Kretz-Rommel A, Qin F, Dakappagari N,
Cofiell R, Faas SJ and Bowdish KS: Blockade of CD200 in the
presence or absence of antibody effector function: implications for
anti-CD200 therapy. J Immunol. 180:699–705. 2008.
|
|
17
|
Xu Y, Sun J, Sheard MA, Tran HC, Wan Z,
Liu WY, Asgharzadeh S, Sposto R, Wu HW and Seeger RC: Lenalidomide
overcomes suppression of human natural killer cell anti-tumor
functions by neuroblastoma microenvironment-associated IL-6 and
TGFβ1. Cancer Immunol Immunother. 62:1637–1648. 2013.
|
|
18
|
Perdomo C, Campbell JD, Gerrein J, Tellez
CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J,
Anderlind C, Jackson GR, Mankus C, Schembri F, O’Hara C, Gomperts
BN, Dubinett SM, Hayden P, Belinsky SA, Lenburg ME and Spira A:
MicroRNA 4423 is a primate-specific regulator of airway epithelial
cell differentiation and lung carcinogenesis. Proc Natl Acad Sci
USA. 110:18946–18951. 2013.
|
|
19
|
Maes E, Landuyt B, Mertens I and Schoofs
L: Interindividual variation in the proteome of human peripheral
blood mononuclear cells. PLoS One. 8:e619332013.
|
|
20
|
Dai YQ, Jin DZ, Zhu XZ and Lei DL:
Triptolide inhibits COX-2 expression via NF-kappa B pathway in
astrocytes. Neurosci Res. 55:154–160. 2006.
|
|
21
|
D’Antonio C, Passaro A, Gori B, Del
Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F:
Bone and brain metastasis in lung cancer: recent advances in
therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
|
|
22
|
Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li
RL, Cao SS, Cui J, Wang L, Wu Y and Wen AD: Regulatory mechanisms
of annexin-induced chemotherapy resistance in cisplatin resistant
lung adenocarcinoma. Asian Pac J Cancer Prev. 15:3191–3194.
2014.
|
|
23
|
Greiner DL, Shultz LD, Yates J, Appel MC,
Perdrizet G, Hesselton RM, Schweitzer I, Beamer WG, Shultz KL,
Pelsue SC, et al: Improved engraftment of human spleen cells in
NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am
J Pathol. 146:888–902. 1995.
|
|
24
|
Hesselton RM, Greiner DL, Mordes JP, Rajan
TV, Sullivan JL and Shultz LD: High levels of human peripheral
blood mononuclear cell engraftment and enhanced susceptibility to
human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid
mice. J Infect Dis. 172:974–982. 1995.
|
|
25
|
Lee YS, Kim TS and Kim DK: T lymphocytes
derived from human cord blood provide effective antitumor
immunotherapy against a human tumor. BMC Cancer. 11:2252011.
|
|
26
|
Liu H, Zhang T, Ye J, Li H, Huang J, Li X,
Wu B, Huang X and Hou J: Tumor-infiltrating lymphocytes predict
response to chemotherapy in patients with advance non-small cell
lung cancer. Cancer Immunol Immunother. 61:1849–1856. 2012.
|
|
27
|
Morris M, Platell C and Iacopetta B:
Tumor-infiltrating lymphocytes and perforation in colon cancer
predict positive response to 5-fluorouracil chemotherapy. Clin
Cancer Res. 14:1413–1417. 2008.
|
|
28
|
Lee WS, Kang M, Baek JH, Lee JI and Ha SY:
Clinical impact of tumor-infiltrating lymphocytes for survival in
curatively resected stage IV colon cancer with isolated liver or
lung metastasis. Ann Surg Oncol. 20:697–702. 2013.
|
|
29
|
Batchelder CA, Duru N, Lee CI, Baker CA,
Swainson L, Mccune JM and Tarantal AF: Myeloid-lymphoid ontogeny in
the rhesus monkey (Macaca mulatta). Anat Rec (Hoboken). May
28–2014.(Epub ahead of print).
|
|
30
|
Fearon ER, Pardoll DM, Itaya T, Golumbek
P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P:
Interleukin-2 production by tumor cells bypasses T helper function
in the generation of an antitumor response. Cell. 60:397–403.
1990.
|
|
31
|
Rosenberg SA: A new era for cancer
immunotherapy based on the genes that encode cancer antigens.
Immunity. 10:281–287. 1999.
|
|
32
|
Al-Shibli KI, Donnem T, Al-Saad S, Persson
M, Bremnes RM and Busund LT: Prognostic effect of epithelial and
stromal lymphocyte infiltration in non-small cell lung cancer. Clin
Cancer Res. 14:5220–5227. 2008.
|
|
33
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012.
|
|
34
|
Donnem T, Al-Shibli K, Andersen S, Al-Saad
S, Busund LT and Bremnes RM: Combination of low vascular
endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and
high lymphocyte infiltration is a strong and independent favorable
prognostic factor in patients with nonsmall cell lung cancer.
Cancer. 116:4318–4325. 2010.
|
|
35
|
Ganesan AP, Johansson M, Ruffell B,
Beltran A, Lau J, Jablons DM and Coussens LM: Tumor-infiltrating
regulatory T cells inhibit endogenous cytotoxic T cell responses to
lung adenocarcinoma. J Immunol. 191:2009–2017. 2013.
|
